WEDNESDAY, March 1, 2017 (HealthDay News) — Exposure to neuraminidase inhibitors during pregnancy is not associated with adverse neonatal outcomes or congenital malformations, according to a study published online Feb. 28 in The BMJ.
Sophie Graner, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life. Data were included for 5,824 exposed women and their infants and 692,232 non-exposed women.
The researchers found that in utero exposure to neuraminidase inhibitors was not associated with elevated risks of low birth weight (adjusted odds ratio [aOR], 0.77; 95 percent confidence interval [CI], 0.65 to 0.91), low Apgar score (aOR, 0.87; 95 percent CI, 0.67 to 1.14), preterm birth (adjusted hazard ratio, 0.97; 95 percent CI, 0.86 to 1.10), small-for-gestational-age birth (aOR, 0.72; 95 percent CI, 0.59 to 0.87), stillbirth (aOR, 0.81; 95 percent CI, 0.51 to 1.30), neonatal mortality (aOR, 1.13; 95 percent CI, 0.56 to 2.28), or neonatal morbidity (aOR, 0.92; 95 percent CI, 0.86 to 1.00). During the first trimester, there was no increased risk of congenital malformations overall in association with maternal exposure (aOR, 1.06; 95 percent CI, 0.77 to 1.48). In analysis restricted to oseltamivir alone, there were no significantly increased risks of any of the outcomes.
“The results support previously reported findings that the use of neuraminidase inhibitors is not associated with increased risks of adverse fetal or neonatal outcomes,” the authors write.
One author disclosed financial ties to the Novo Nordisk Foundation.
Copyright © 2017 HealthDay. All rights reserved.